- Conditions
- Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic Leukemia, t(9;22)
- Interventions
- Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin, Methotrexate, Prednisone, Vincristine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 241–264
of 1,251
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Desmoplastic Small Round Cell Tumor
- Interventions
- Ramucirumab, Cyclophosphamide, Vinorelbine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 12 Months to 29 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 3 more
- Conditions
- Non-Hodgkin's B-cell Lymphoma, Lymphoma Non-Hodgkin, Diffuse Large B-Cell Lymphoma (DLBCL)
- Interventions
- Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisolone (R-CHOP), Epcoritamab, Dexamethasone, Positron Emission Tomography (PET), Blood specimen collection, Questionnaires, Computerized tomography (CT)
- Drug · Procedure · Behavioral
- Lead sponsor
- Carrie Ho, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- San Francisco, California
- Conditions
- Non - Small Cell Lung Cancer NSCLC
- Interventions
- MEDI4736 (durvalumab), Vinorelbine, Gemcitabine, Erlotinib, MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4), tremelimumab (anti-CTLA4)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 597 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 33
- States / cities
- Chandler, Arizona • Anaheim, California • Duarte, California + 29 more
- Conditions
- B-cell Acute Lymphoblastic Leukemia
- Interventions
- Inotuzumab ozogamicin, Prednisone Pill, Daunorubicin, Vincristine, Cytarabine, Methotrexate, Pegaspargase
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 16 Years to 60 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 4
- States / cities
- Nashville, Tennessee • Charlottesville, Virginia • Richmond, Virginia + 1 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Erlotinib, Platinum-based chemotherapy
- Drug
- Lead sponsor
- New Mexico Cancer Research Alliance
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 5
- States / cities
- Albuquerque, New Mexico • Santa Fe, New Mexico
- Conditions
- Pleuropulmonary Blastoma
- Interventions
- Biospecimen Collection, Bone Scan, Computed Tomography, Cyclophosphamide, Dactinomycin, Dexrazoxane, Doxorubicin, Echocardiography Test, Ifosfamide, Magnetic Resonance Imaging, Multigated Acquisition Scan, Patient Observation, Positron Emission Tomography, Topotecan, Ultrasound Imaging, Vincristine
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 80
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 71 more
- Conditions
- Hodgkin Disease
- Interventions
- Doxorubicin, Vinblastine, Cyclophosphamide, Etoposide, Vincristine, Bleomycin, Gemcitabine, Vinorelbine, Prednisone
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- Rituximab, Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,418 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 32 more
- Conditions
- Obsessive-Compulsive Disorder
- Interventions
- Psilocybin 10 mg, Psilocybin 20 mg, Psilocybin 30 mg
- Drug
- Lead sponsor
- Francisco A Moreno
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- PTSD, Stress Disorders, Traumatic, Stress Disorders, Post-Traumatic, Trauma and Stressor Related Disorders, Mental Disorder
- Interventions
- Psilocybin
- Drug
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 21 Years to 64 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- T-cell Childhood Acute Lymphoblastic Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia
- Interventions
- prednisone, vincristine sulfate, daunorubicin hydrochloride, asparaginase, methotrexate, cyclophosphamide, cytarabine, mercaptopurine, leucovorin calcium, dexamethasone, doxorubicin hydrochloride, thioguanine, radiation therapy, nelarabine, pegaspargase, pharmacological study, laboratory biomarker analysis
- Drug · Radiation · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Arcadia, California
- Conditions
- Cocaine Related Disorders
- Interventions
- Yohimbine, Placebo
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Lung Cancer
- Interventions
- bevacizumab, vinorelbine tartrate
- Biological · Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 70 Years to 120 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Psychedelic Effects in Healthy Volunteers
- Interventions
- Pindolol, Placebo, Psilocybin
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 21 Years to 60 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Lung Cancer
- Interventions
- topotecan hydrochloride, vinorelbine tartrate
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Hodgkin Lymphoma
- Interventions
- bendamustine, Etoposide, Doxorubicin, Bleomycin, Vincristine, Vinblastine, Prednisone, Filgrastim, Brentuximab Vedotin, Cyclophosphamide, DTIC, Quality of Life Measurements, Radiotherapy
- Drug · Other · Radiation
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 25 Years
- Enrollment
- 232 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 8
- States / cities
- Palo Alto, California • Peoria, Illinois • Baton Rouge, Louisiana + 4 more
- Conditions
- Rapidly Escalating Migraine
- Interventions
- DFN-11
- Drug
- Lead sponsor
- Dr. Reddy's Laboratories Limited
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Springfield, Missouri
- Conditions
- Improving Cardiometabolic Outcomes in Older Adults
- Interventions
- Melatonin 1 mg, Placebos, Meal timing, Non-Meal timing
- Dietary Supplement · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 55 Years to 75 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Prostate Cancer
- Interventions
- Estramustine, Vinorelbine
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Sarcoma, Neuroblastoma, Wilms Tumor, Leukemia, Lymphoma, Brain Tumors
- Interventions
- Marqibo
- Drug
- Lead sponsor
- Acrotech Biopharma Inc.
- Industry
- Eligibility
- 2 Years to 20 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Peripheral T Cell Lymphoma
- Interventions
- Golidocitinib, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hodgkin Lymphoma
- Interventions
- Brentuximab Vedotin, Doxorubicin, Vincristine, Rituximab
- Drug
- Lead sponsor
- Mitchell Cairo
- Other
- Eligibility
- 1 Year to 29 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Valhalla, New York
- Conditions
- Refractory Solid Tumors, Relapsed Solid Tumors, Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Rhabdomyosarcoma, Refractory Rhabdomyosarcoma
- Interventions
- PEEL-224, Vincristine, Temozolomide (TMZ)
- Drug
- Lead sponsor
- Theodore Laetsch
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 7
- States / cities
- Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more